Advanced search
Publication Cover
Immunological Medicine Volume 44, 2021 - Issue 2
Submit an article Journal homepage
2,216
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma

Terufumi Kuboa Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9274-2551
ORCID Icon,
Taro Sugawarab Department of Surgical Pathology, Sapporo Medical University Hospital, Sapporo, Japan
,
Tomoyo Shinkawaa Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Tomoyo Kurisuc Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Nodoka Kouzenc Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Toshiaki Tanakac Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Fumimasa Fukutac Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Kouji Yamasakic Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Shintaro Sugitab Department of Surgical Pathology, Sapporo Medical University Hospital, Sapporo, Japan
,
Kazuhiko Matsuod Sapporo Clinical Laboratory Inc., Sapporo, Japan
,
Rena Moritaa Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Yoshihiko Hirohashia Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Tomohide Tsukaharaa Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Takayuki Kanasekia Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
,
Tadashi Hasegawab Department of Surgical Pathology, Sapporo Medical University Hospital, Sapporo, Japan
,
Naoya Masumoric Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan
&
Toshihiko Torigoea Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
 show all
Pages 136-141 | Received 19 Feb 2020, Accepted 23 Jun 2020, Published online: 07 Jul 2020

References

  • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
  • De Velasco G, Je Y, Bosse D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312–318.
  • Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19):e59125.
  • Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA. 2017;114(19):4993–4998.
  • Kubo T, Hirohashi Y, Matsuo K, et al. Mismatch repair protein deficiency is a risk factor for aberrant expression of HLA class I molecules: a putative adaptive immune escape phenomenon. Anticancer Res. 2017;37(3):1289–1295.
  • Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncol. 2016;17(11):1558–1568.
  • Tian Y, Abu-Sbeih H, Wang Y. Immune checkpoint inhibitors-induced hepatitis. Adv Exp Med Biol. 2018;995:159–164.
  • Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO + IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7(1):341.
  • Zhao C, Tella SH, Del Rivero J, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018;103(2):365–369.
  • Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
  • Brilli L, Danielli R, Ciuoli C, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58(3):535–541.
  • Postow MA, Hellmann MD. Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(12):1165.
  • Martincorena I, Fowler JC, Wabik A, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362(6417):911–917.
  • Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25(8):1243–1250.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.